ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of “Hold” from Brokerages

ImageneBio, Inc. (NASDAQ:IMA) has earned an average rating of “Hold” from the five analysts that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $29.00.

Several research analysts have issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. HC Wainwright initiated coverage on ImageneBio in a research note on Friday, August 21st. They issued a “buy” rating and a $28.00 price objective for the company.

Institutional Trading of ImageneBio

Several hedge funds have recently modified their holdings of IMA. Blue Owl Capital Holdings LP bought a new position in ImageneBio during the second quarter valued at $5,414,000. Monashee Investment Management LLC bought a new position in shares of ImageneBio during the fourth quarter valued at approximately $632,000. Trails Edge Capital Partners LP bought a new position in ImageneBio in the 2nd quarter valued at $1,663,824. Cable Car Capital LP bought a new position in shares of ImageneBio in the second quarter worth about $4,611,000. Finally, Stonepine Capital Management LLC purchased a new position in ImageneBio in the 2nd quarter worth about $539,044,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Stock Down 1.6%

Shares of NASDAQ IMA opened at $5.00 on Tuesday. The firm’s 50-day moving average price is $5.55 and its 200-day moving average price is $5.66. The company has a market cap of $56.76 million, a PE ratio of -1.09 and a beta of 0.70. ImageneBio has a 52-week low of $3.94 and a 52-week high of $9.20.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.27. As a group, equities research analysts anticipate that ImageneBio will post -3.23 EPS for the current fiscal year.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.